Global Life Science Ventures — Investing in the life sciences

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.

Home  Sitemap  Imprint

Download area

Background Information

• Fact sheet
• Extended biographies
• List of portfolio companies

Articles & Presentations

• Investment in European Biotech: Outlook and Trends
• Dr. Peter Reinisch's presentation at the 2006 Biotech in Europe Investor Forum, featuring the results of the GLSV Biotech Investment Barometer
• Herausforderung Finanzierung - Biotech Firmen in Europa. Hanns-Peter Wiese, Going Public September 2006
• The impact of biotechnology on modern healthcare and drug development
  Peter Reinisch, partner of Global Life Science Ventures, argues that biotechnology will play a decisive role in the development of the healthcare sector - Privateequityonline July 2006
  
• After the Hype: The Horizons for Biotech
  Hanns-Peter Wiese at Global Life Science Ventures scans the future in his examination of likely funding scenarious for 2006 - ebr Bio-Finance and Management spring 2006
• Early-Late Companies: The New Sweet Spor For European Biotech Venture Capitalists? - EVCJ April 2006
• State of Industry Discussed at BIO-Europe - GEN BioBusiness 15. January 2006.
• An Opportunity to Invest in Europe - business guide to Switzerland 1/2006.
• Many companies have products in Phase II or Phase III - Dr. Hans A. Küpper, Partner & Hanns-Peter Wiese, Partner, Global Life Science Ventures - Biotechnologies & Finances, December 2005 (page 8)
• Dr. Peter Reinisch's presentation, featuring the results of GLSV Biotech Investment Barometer at the 2005 Biotech in Europe Investor Forum.
• Global Life Science Ventures has achived a sound track record through discerning investments in high potential companies - EVCJ Sept 2005.
• Biotechnology in Europe: Turning the Corner . EVCJ Sept. 2005.
• Interview mit Dr. Hans Küpper und Hans-Peter Wiese im Going Public Magazin, Sonderausgabe "Biotechnologie 2005" im September 2005. "Biotechunternehmen scheinen zunehmend der Antrieb für das Wachstum in der Biopharmabranche zu sein.
• Interview mit Dr. Peter Reinisch in Families in Business Sept/Oct 2005, The Science of Biotechnology/Investing.
• Business Guide to Switzerland "Entrepreneurship is Alive and Well in Switzerland
• Hans Küpper discusses science and venture capital - Drugsdiscoverytoday.com, Nov. 2004